Riskpilot← Back to searchSign inGet full accessPHARMATECHPOWER ApS
APSActiveCVR 32880363Skodsborg Strandvej 150, st. tvEngineering activities and related technical consultancy · NACE 7112Est. 20101 employees
Revenue 2025
DKK 36K
-90% vs 2024
EBITDA margin
13.5%
-98% vs 2024
Equity ratio
-13.1%
Financial strength
Net profit 2025
DKK 4K
-99% vs 2024
| Revenue | DKK 36K | -90% |
| EBITDA | DKK 5K | -98% |
| Net profit | DKK 4K | -99% |
| Total assets | DKK 769K | +77% |
| Equity | DKK -101K | +4% |
| Employees | 1 | — |
Legal name
PHARMATECHPOWER ApS
CVR number
32880363
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
21. april 2010
Share capital
DKK 80.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren
Company purpose
Selskabets formål er at drive ingeniørvirksomhed i bred forstand
Address
Skodsborg Strandvej 150, st. tv
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.335 | 5.345 | 4.170 | 2.126 | 1.646 | 565 | 61 | -1 | 27 | 1.057 | 43 | 349 | 36 |
| Staff expenses | -2.522 | -3.796 | -3.491 | -1.989 | -1.695 | -801 | -52 | -2 | -1 | -2 | -0 | -61 | -31 |
| EBITDA | 813 | 1.549 | 679 | 137 | -49 | -236 | 9 | -3 | 26 | 82 | 43 | 288 | 5 |
| Depreciation & amort. | -0 | -55 | -55 | -55 | -55 | -55 | -55 | -55 | -55 | -15 | -0 | -0 | -0 |
| EBIT | 813 | 1.494 | 624 | 82 | -104 | -291 | -46 | -58 | -29 | 67 | 43 | 288 | 5 |
| Net financials | 0 | -1 | 0 | 0 | 0 | 0 | -1 | -1 | -0 | -1 | -101 | 0 | 0 |
| Profit before tax | 813 | 1.494 | 624 | 82 | -104 | -291 | -47 | -59 | -29 | 67 | -58 | 288 | 5 |
| Tax | 201 | 415 | 162 | 18 | -0 | -0 | -0 | -0 | -0 | 15 | -0 | -0 | 1 |
| Net profit | 612 | 1.079 | 462 | 64 | -104 | -291 | -47 | -59 | -29 | 52 | -58 | 288 | 4 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.040 | 3.673 | 1.434 | 516 | 654 | 223 | 175 | 112 | 91 | 218 | 381 | 433 | 769 |
| Equity | 952 | 2.031 | 542 | 144 | 40 | -252 | -299 | -357 | -387 | -335 | -393 | -105 | -101 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.087 | 1.627 | 870 | 350 | 615 | 475 | 474 | 470 | 478 | 553 | 773 | 538 | 869 |
| Total debt | 1.087 | 1.627 | 870 | 350 | 615 | 475 | 474 | 470 | 478 | 553 | 773 | 538 | 869 |
EBITDA margin
13.5%
This company
15.8%
Market median
-15% vs market
20132025
Equity ratio
-13.1%
This company
38.2%
Market median
-134% vs market
20132025
Return on equity
379200.0%
This company
18.4%
Market median
+2060770% vs market
20132025
Net profit margin
10.5%
This company
8.1%
Market median
+30% vs market
20132025
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
20132025
Debt / equity
8.63×
This company
0.62×
Market median
-1292% vs market
20132025
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via CVR / Virk · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via CVR / Virk · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via CVR / Virk · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via CVR / Virk · Period 2017-04-01 – 2018-03-31
- Annual report 2017Filed via CVR / Virk · Period 2016-04-01 – 2017-03-31
- Annual report 2016Filed via CVR / Virk · Period 2015-04-01 – 2016-03-31
- Annual report 2015Filed via CVR / Virk · Period 2014-04-01 – 2015-03-31
- Annual report 2014Filed via CVR / Virk · Period 2013-04-01 – 2014-03-31
- Annual report 2013Filed via CVR / Virk · Period 2012-04-01 – 2013-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
MFA + JENSEN 2000 HOLDING ApS | Company | 100.0% | 100.0% | 2010 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MFA + JENSEN 2000 HOLDING ApS
PHARMATECHPOWER ApS Board members of PHARMATECHPOWER ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jesper Mak | Chief Executive Officer | 0 companies |